Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUPI REDUCE trial
2023-504171-24-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Mean Eczema Area and Severity Index (EASI) at week 16. Planned start Jun 2023; status: authorised.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-504171-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504171-24-00.